{"id":"gestrinone","rwe":[],"tags":[{"label":"gestrinone","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Sex hormone-binding globulin","category":"target"},{"label":"SHBG","category":"gene"},{"label":"G03XA02","category":"atc"},{"label":"Active","category":"status"},{"label":"Contraceptive Agents","category":"pharmacology"},{"label":"Contraceptive Agents, Female","category":"pharmacology"},{"label":"Contraceptive Agents, Hormonal","category":"pharmacology"},{"label":"Contraceptives, Oral, Hormonal","category":"pharmacology"},{"label":"Hormones","category":"pharmacology"},{"label":"Progestins","category":"pharmacology"},{"label":"Reproductive Control Agents","category":"pharmacology"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"dimetrose","offLabel":[],"synonyms":["gestrinone","dimetriose","dimetrose","nemestran","tridomose"],"timeline":[],"aiSummary":"Dimetrose, also known as gestrinone, is a small molecule drug that targets sex hormone-binding globulin. It is a gestrinone, a class of drugs that mimic the effects of sex hormones. Gestrinone is used to treat conditions such as endometriosis and fibrocystic breast disease. The commercial status of gestrinone is unclear, and it may be patented or have generic manufacturers. Key safety considerations include unknown half-life and bioavailability.","approvals":[],"brandName":"Dimetrose","ecosystem":[],"mechanism":{"target":"Sex hormone-binding globulin","targets":[{"gene":"SHBG","source":"DrugCentral","target":"Sex hormone-binding globulin","protein":"Sex hormone-binding globulin"}],"modality":"Small Molecule","drugClass":"gestrinone","explanation":"Think of sex hormone-binding globulin like a key that unlocks the door to sex hormones. Gestrinone is a key that fits into this lock, allowing sex hormones to be released and have their effects on the body. This can help to treat conditions like endometriosis and fibrocystic breast disease.","oneSentence":"Gestrinone works by binding to sex hormone-binding globulin, a protein that regulates the levels of sex hormones in the body.","technicalDetail":"Gestrinone is a nonsteroidal, potent agonist of the progesterone receptor, which leads to the downregulation of sex hormone-binding globulin, resulting in increased levels of free sex hormones."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1292","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=GESTRINONE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=GESTRINONE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T11:44:46.494904","biosimilars":[],"competitors":[{"drugName":"danazol","drugSlug":"danazol","fdaApproval":"1976-06-21","genericCount":3,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"gestrinone","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"danazol","brandName":"danazol","genericName":"danazol","approvalYear":"1976","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT05570786","phase":"PHASE2","title":"Subdermal Implant-bioabsorbable Gestrinone Pellet for Endometriosis Pelvic Pain Treatment","status":"COMPLETED","sponsor":"Science Valley Research Institute","startDate":"2023-02-13","conditions":["Deep Endometriosis","Pelvic Pain"],"enrollment":100,"completionDate":"2025-10-31"},{"nctId":"NCT06402344","phase":"","title":"Gestrinone and Endothelial Function in Young Women","status":"RECRUITING","sponsor":"Hospital Israelita Albert Einstein","startDate":"2024-08-22","conditions":["Cardiovascular Diseases"],"enrollment":90,"completionDate":"2025-12-30"},{"nctId":"NCT06543550","phase":"PHASE4","title":"Comparison Between the Effects of Implantable Gestrinone and Oral Dienogest in the Treatment of Endometriosis","status":"RECRUITING","sponsor":"Bio Meds Pharmaceutica Ltda","startDate":"2024-07-30","conditions":["Endometriosis"],"enrollment":70,"completionDate":"2025-10"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"NUI":"N0000167403","NDDF":"003973","UNII":"1421533RCM","CHEBI":"CHEBI:89642","INN_ID":"4285","RXNORM":"4792","UMLSCUI":"C0017507","ChEMBL_ID":"CHEMBL1868702","KEGG_DRUG":"D04317","DRUGBANK_ID":"DB11619","PUBCHEM_CID":"27812","SNOMEDCT_US":"387589005","MESH_DESCRIPTOR_UI":"D005867"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":222,"therapeuticAreas":["Other"],"atcClassification":{"source":"DrugCentral","atcCode":"G03XA02","allCodes":["G03XA02"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}